Join our 20.000 subscribers and receive the monthly newsletter for free!

RELATED ARTICLES
RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Watch out for Lyme disease!

Summer is coming, it’s getting warmer, and you’re planning on outdoor activities. Unfortunately, ticks are getting out there as well, and your cha…


Coris Bioconcept diagnoses antibiotic resistance

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chrom…

POPULAR TAGS

Ebola diagnostics – faster, safer, and more accurate

Written by GK on in the category Insights with the tags , , .


“Last year the Ebola outbreak kick-started the development of a fast and accurate Ebola test to be used with Biocartis’ Idylla™ platform” - says Daap Kooij (Janssen Diagnostics). “We expect the test developed in partnership with Biocartis to be ready for clinical use by Q4 of 2015 as an FDA approved EUA product. It will initially target the African market where it will bring otherwhise complex testing with the simplicity of Idylla™ to the hands of its healthcare professionals.”

In partnership with Biocartis and the Institute of Tropical Medicine in Antwerp, Janssen Diagnostics is developing and will commercialize certain assays for infectious diseases to be used with Idylla™. One of such tests is an Ebola diagnostic assay, detecting the Zaire and Sudan Ebola strains. Validation testing of virus samples in Belgium and the US is currently in its final stage.

It only requires a blood sample

The Ebola test uses a 0,2 ml anti-coagulated blood sample, which is added to the cartridge. The cartridge contains all necessary reagents for the fully automated detection of viral RNA in the patient’s blood. A complete sample analysis can be performed outside of the specialized laboratory, making the test ideal for use in regions with limited infrastructure. Moreover, the cartridge does not even need to be refrigerated, which is advantageous in regions with warm climates. The whole Idylla™ system is extremely user friendly and the operator doesn’t need any special training. Kooij comments: “The whole beauty of this platform is that it opens up the possibilities to run molecular diagnostics at virtually any place. Even when electricity is not available, Idylla™ will continue to operate by external batteries or solar energy.”

Safe for the healthcare professionals

The Ebola outbreak, which occurred last year, exposed an urgent need for fast and accurate diagnostics. Most of the Ebola tests (EUA approved) that are currently in use are based on manual extraction of viral RNA from patient’s blood, plasma or serum. Handling potentially infected blood samples is both time-consuming and cumbersome for healthcare personnel.  In the Idylla™ cartridge, sample preparation happens automatically in the cartridge without involvement of the operator. “The user interaction of the healthcare professional is limited to less than 2 minutes hands-on time consisting of scanning and inserting the sample in the cartridge. The lid, once in closed position, cannot be reopened. This is very important in terms of safety and avoiding cross-contamination of the sample. After completing the test, the whole cartridge is discarded into a biohazard container,” explains Kooij.

By September the tests should be ready for clinical use. In the meantime, the Ebola outbreak has largely been controlled. This creates a new challenge for widespread deployment of the tests once available. “In addition to selling to customers through a traditional commercial approach, we are looking for partnerships with non for profit organizations, foundations, institutions like WHO, UNICEF, and Médecins Sans Frontières.”

(Image: Ebola virus (green, isolated in November 2014 from patient’s blood sample in Mali) on the surface of the cell. Credit: NIAID, flickr.com)

Read more about: , , .

RELATED ARTICLES
RSV OR THE FLU? NOW YOU KNOW IT IMMEDIATELY

Janssen Diagnostics has developed a molecular diagnostic test which will be used with the Biocartis’ Idylla™ platform, to determine Influenza and …


Watch out for Lyme disease!

Summer is coming, it’s getting warmer, and you’re planning on outdoor activities. Unfortunately, ticks are getting out there as well, and your cha…


Coris Bioconcept diagnoses antibiotic resistance

With almost 20 years of experience, Coris BioConcept knows the world of infectious disease diagnostics inside and out. Their straightforward chrom…

POPULAR TAGS

Sign up to our Mailing List to receive updates
of our latest News, Events & Magazines

XpandInnovation V-Bio Ventures Itera Life Science KU Leuven Janssen Turnstone Flanders.bio Biowin UGent GSK

ABOUT BIOVOX - Sharing Life Sciences Innovations

BioVox showcases interesting life sciences breakthroughs for and from Belgian innovators. Through our partnership with BioCentury we share relevant worldwide innovations and business updates while our local journalists focus on regional highlights. 

Interested to get involved? Get in touch! We are looking for content, writers and partners! Blogs are available for research institutes, companies and freelance experts.

You want to reach out to the biotechnology and life sciences community, targetting selected audiences? Discover our sponsor and publication opportunities as well as tailored packages!

Contact BioVox via news@biovox.be or by completing the contact form.